Natixis Advisors, L.P. Kymera Therapeutics, Inc. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 14,378 shares of KYMR stock, worth $586,909. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,378Holding current value
$586,909% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$271 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$245 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$211 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$200 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$194 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.23B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...